Andrew G. Renehan

Andrew G. Renehan

Auto-generated profile, based on publicly available information

Andrew G. Renehan

Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in The Lancet
Verified
Journal Article
Closed access
ARAndrew G Renehan
Andrew G Renehan
MTMargaret Tyson
Margaret Tyson
MEMatthias Egger
Matthias Egger
RHRichard F Heller
Richard F Heller
MZMarcel Zwahlen
Marcel Zwahlen

1 April 2004 in The Lancet
Verified
Journal Article
Closed access
ARAndrew G Renehan
Andrew G Renehan
MZMarcel Zwahlen
Marcel Zwahlen
CMChristoph Minder
Christoph Minder
SOSarah T O'Dwyer
Sarah T O'Dwyer
SSStephen M Shalet
Stephen M Shalet
MEMatthias Egger
Matthias Egger

1 January 2015 in The Lancet Oncology
Verified
Journal Article
Open access
MAMelina Arnold
Melina Arnold
NPNirmala Pandeya
Nirmala Pandeya
GBGraham Byrnes
Graham Byrnes
ARAndrew G Renehan
Andrew G Renehan
GSGretchen A Stevens
Gretchen A Stevens
ISIsabelle Soerjomataram
Isabelle Soerjomataram
High body-mass index (BMI; defined as 25 kg/m(2) or greater) is associated with increased risk of cancer. To inform public health policy and future research, we estimated the global burden of cancer attributable to high BMI in 2012. In this population-based study, we derived population attributable fractions (PAFs) using relative risks and BMI estimates in adults by age, sex, and country. Assuming a 10-year lag-period between high BMI and cancer occurrence, we calculated PAFs using BMI estimates from 2002 and used GLOBOCAN2012 data to estimate numbers of new cancer cases attributable to high BMI. We also calculated the proportion of cancers that were potentially avoidable had populations maintained their mean BMIs recorded in 1982. We did secondary analyses to test the model and to estimate the effects of hormone replacement therapy (HRT) use and smoking. Worldwide, we estimate that 481,000 or 3.6% of all new cancer cases in adults (aged 30 years and older after the 10-year lag period) in 2012 were attributable to high BMI. PAFs were greater in women than in men (5.4% vs 1.9%). The burden of attributable cases was higher in countries with very high and high human development indices (HDIs; PAF 5.3% and 4.8%, respectively) than in those with moderate (1.6%) and low HDIs (1.0%). Corpus uteri, postmenopausal breast, and colon cancers accounted for 63.6% of cancers attributable to high BMI. A quarter (about 118,000) of the cancer cases related to high BMI in 2012 could be attributed to the increase in BMI since 1982. These findings emphasise the need for a global effort to abate the increasing numbers of people with high BMI. Assuming that the association between high BMI and cancer is causal, the continuation of current patterns of population weight gain will lead to continuing increases in the future burden of cancer. World Cancer Research Fund International, European Commission (Marie Curie Intra-European Fellowship), Australian National Health and Medical Research Council, and US National Institutes of Health.

1 February 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
ARAndrew G Renehan
Andrew G Renehan
LMLee Malcomson
Lee Malcomson
RERichard Emsley
Richard Emsley
SGSimon Gollins
Simon Gollins
AMAndrew Maw
Andrew Maw
SOSarah T O'DWyer
Sarah T O'DWyer

24 July 2015 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
ARAndrew G. Renehan
Andrew G. Renehan
MZMarcel Zwahlen
Marcel Zwahlen
MEMatthias Egger
Matthias Egger

6 April 2002 in BMJ
Verified
Journal Article
Closed access
PDF file
ARAndrew G Renehan
Andrew G Renehan
MEMatthias Egger
Matthias Egger
MSMark P Saunders
Mark P Saunders
SOSarah T O'DWyer
Sarah T O'DWyer
Objective: To review the evidence from clinical trials of follow up of patients after curative resection for colorectal cancer. Design: Systematic review and meta-analysis of randomised controlled trials of intensive compared with control follow up. Main outcome measures: All cause mortality at five years (primary outcome). Rates of recurrence of intraluminal, local, and metastatic disease and metachronous (second colorectal primary) cancers (secondary outcomes). Results: Five trials, which included 1342 patients, met the inclusion criteria. Intensive follow up was associated with a reduction in all cause mortality (combined risk ratio 0.81, 95% confidence interval 0.70 to 0.94, P=0.007). The effect was most pronounced in the four extramural detection trials that used computed tomography and frequent measurements of serum carcinoembryonic antigen (risk ratio 0.73, 0.60 to 0.89, P=0.002). Intensive follow up was associated with significantly earlier detection of all recurrences (difference in means 8.5 months, 7.6 to 9.4 months, P<0.001) and an increased detection rate for isolated local recurrences (risk ratio 1.61, 1.12 to 2.32, P=0.011). Conclusions: Intensive follow up after curative resection for colorectal cancer improves survival. Large trials are required to identify which components of intensive follow up are most beneficial. What is already known on this topic: There is a lack of direct evidence that intensive follow up after initial curative treatment for colorectal cancer leads to increased survival Guidelines are inconclusive and clinical practice varies widely What this study adds: The cumulative analysis of available data supports the view that intensive follow up after curative resection for colorectal cancer improves survival If computed tomography and frequent measurements of serum carcinoembryonic antigen are used during follow up mortality related to cancer is reduced by 9-13% This survival benefit is partly attributable to the earlier detection of all recurrences, particularly the increased detection of isolated recurrent disease